NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

The reason is simply. Those who criticize DCVax-L have deep interest in something else which DCVax-L is going to make obsolete. That's why they are so desperate.

Simply check the insider sell records from C-suite of NVCR and specifically focus on the two time lines: May of 2018 and November of 2022 You can get an idea on how panic they are.

Take a look at those cancer vaccines based on neoantigens from Moderna and BNTX. Those tumor-specific antigens that their vaccines present to T cells can certainly be loaded by DCVax-L and present them to T cells. It should be noted that those vaccines have to be loaded with antigens that can only be found in tumor cells and not in normal cells. How can they be so sure given the complexity of human body? What if one of the antigen can be found in normal cells?

That's why DCVax-L is so amazing. It can be loaded all tumor associated antigens, antigens that include tumor specific ones and the ones that can be found in both tumor cells and normal cells. Obviously, the maturated and excited dendritic cells primed by NWBO technology have comprehensive information about tumor cells so that t-cells can do, so to speak, a 3d holographic scan on tumor cell and normal cell to identify which one is the real target.

There were 31 clinical trials on dendritc cell vaccines using lysate pulsed approach. Only one can be called break-through. It is DCVax-L.